Additional Proxy Soliciting Materials (definitive) (defa14a)
July 22 2022 - 4:37PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14A INFORMATION
Proxy
Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No.   )
Filed
by the Registrant x
Filed
by a Party other than the Registrant ¨
Check
the appropriate box:
¨ Preliminary
Proxy Statement
¨ Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2))
¨ Definitive
Proxy Statement
x Definitive Additional Materials
¨ Soliciting Material Pursuant
to Section 240.14a-11 (c) or Section 240.14a-12
NEUBASE
THERAPEUTICS, INC.
(Name
of Registrant as Specified in its Charter)
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment
of Filing Fee (Check all boxes that apply):
x No
fee required.
¨ Fee paid previously with
preliminary materials.
¨ Fee computed on table in
exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
| NeuBase Therapeutics, Inc.
Important Notice Regarding the Availability
of Proxy Materials
Stockholders Meeting to be held on
September 8, 2022
For Stockholders of record as of July 15, 2022
Have the 12 digit control number located in the shaded box above available
when you access the website and follow the instructions.
When requesting via the Internet or telephone you will need the 12 digit
control number located in the shaded box above.
* If requesting material by e-mail, please send a blank
e-mail with the 12 digit control number (located above)
in the subject line. No other requests, instructions OR
other inquiries should be included with your e-mail
requesting material.
NeuBase Therapeutics, Inc.
Meeting Type:
Date:
Time:
Place:
Annual Meeting of Stockholders
Thursday, September 8, 2022
8:30 AM, Eastern Time
Annual meeting to be held live via the Internet
Please visit www.proxydocs.com/NBSE for more details
You must register to attend the meeting online and/or participate at www.proxydocs.com/NBSE
SEE REVERSE FOR FULL AGENDA
INTERNET
www.investorelections.com/NBSE
TELEPHONE
(866) 648-8133
* E-MAIL
paper@investorelections.com
To order paper materials, use one of the following methods.
For a convenient way to view proxy materials and VOTE go to
www.proxydocs.com/NBSE
If you want to receive a paper or e-mail copy of the proxy material, you must request one. There
is no charge to you for requesting a copy. In order to receive a paper package in time for this
year's meeting, you must make this request on or before August 29, 2022.
This communication presents only an overview of the more
complete proxy materials that are available to you on the Internet.
This is not a ballot. You cannot use this notice to vote your shares.
We encourage you to access and review all of the important
information contained in the proxy materials before voting.
To view the proxy materials, and to obtain directions to attend the
meeting, go to: www.proxydocs.com/NBSE
To vote your proxy while visiting this site, you will need the 12
digit control number in the box below.
Under United States Securities and Exchange Commission rules, proxy
materials do not have to be delivered in paper. Proxy materials can be
distributed by making them available on the internet.
P.O. BOX 8016, CARY, NC 27512-9903 |
| NeuBase Therapeutics, Inc.
Annual Meeting of Stockholders
PROPOSAL
1. To elect two Class II directors, Dietrich Stephan, Ph.D. and Gerry J. McDougall, nominated by our Board of Directors, to serve until our 2025
Annual Meeting of Stockholders and until their successors are duly elected and qualified
1.01 Dietrich Stephan Ph.D.
1.02 Gerry J. McDougall
2. Ratify the selection by the Audit Committee of the Board of Directors of Marcum LLP as the Company's independent registered public accounting firm for its fiscal year ending September 30, 2022
3. Advisory vote to approve named executive officer compensation
4. Approval of a series of alternate amendments to the Company's amended and restated certificate of incorporation to effect, at the discretion of
the Company's Board of Directors, a reverse split of the Company's common stock, whereby each outstanding 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19 or 20 shares would be combined, converted and changed into one share of common stock.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE:
FOR ON PROPOSALS 1, 2, 3 AND 4 |
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Apr 2023 to Apr 2024